Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 10:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 1,097 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Repeat Testing Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Molecular Transducers of Physical Activity Consortium

NCT03960827
View directory record Official record
Conditions
Physical Activity
Interventions
EE Training, RE Training
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
1,836 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 29, 2026, 10:26 AM EDT
Terminated Not applicable Interventional

Neuromodulation of Ankle Muscles in Persons With SCI

NCT04238013
View directory record Official record
Conditions
Spinal Cord Injuries, Spastic Gait, Foot Drop
Interventions
Whole Body Vibration (WBV), Electrical Stimulation
Other
Lead sponsor
Shepherd Center, Atlanta GA
Other
Eligibility
18 Years to 85 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Oct 29, 2026, 10:26 AM EDT
Completed No phase listed Observational

Aldosterone Renin Ratio (ARR) Test to Increase Case-detection of Primary Aldosteronism (PA)

NCT05757076
View directory record Official record
Conditions
Primary Aldosteronism
Interventions
Blood test for ARR
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
53 participants
Timeline
2023 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 29, 2026, 10:26 AM EDT
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

Therapeutic Strategies to Reduce Endothelial Ischemia-reperfusion Injury

NCT06825143
View directory record Official record
Conditions
Metabolic Syndrome, Vascular Injury, Ischemic Preconditioning, Endothelial Function (reactive Hyperemia), Endothelial Dysfunction
Interventions
Ischemic preconditioning, Intravenous lactate infusion, No ischemic preconditioning (control), Normal Saline Infusion (Placebo), Ischemic preconditioning and intravenous lactate
Procedure · Drug · Combination Product
Lead sponsor
Gary Van Guilder
Other
Eligibility
18 Years to 65 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Gunnison, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 29, 2026, 10:26 AM EDT
Completed Early Phase 1 Interventional

Respiratory Strength Training in Persons With Amyotrophic Lateral Sclerosis (ALS)

NCT02710110
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
PowerLung trainer, Micro Mouth Pressure Meter, Pulmonary Function Testing, Videofluoroscopic swallowing study, Swallowing Quality of Life Questionnaire, Iowa Oral Pressure Instrument, Capsaicin
Device · Procedure · Other + 1 more
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 29, 2026, 10:26 AM EDT
Completed Not applicable Interventional

Treatment of Hemiparetic Gait Impairments Using Telehealth With the Moterum iStride Solution™

NCT04434313
View directory record Official record
Conditions
Telemedicine, Gait, Hemiplegic, Gait Disorders, Neurologic, Stroke, Orthotic Devices, Gait Analysis
Interventions
Delivery of iStride™ device gait treatment using telemedicine
Device
Lead sponsor
Moterum Technologies, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 7, 2022 · Synced Oct 29, 2026, 10:26 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS)

NCT03733990
View directory record Official record
Conditions
Cancer
Interventions
FP-1305 (bexmarilimab)
Biological
Lead sponsor
Faron Pharmaceuticals Ltd
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Oct 29, 2026, 10:26 AM EDT
Terminated Phase 2 Interventional Results available

Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma

NCT04527549
View directory record Official record
Conditions
Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Unresectable Melanoma
Interventions
Dabrafenib mesylate, Hydroxychloroquine, Placebo Administration, Trametinib dimethyl sulfoxide
Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
199
States / cities
Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 139 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 29, 2026, 10:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Human Photoallergy Test

NCT02750449
View directory record Official record
Conditions
Sunscreening Agents
Interventions
Sun screening Sport Lotion, (BAY987516), Untreated skin
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 60 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Oct 29, 2026, 10:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

CVCTPlus: A Couples-Based Approach to Linkage to Care and ARV Adherence

NCT01772992
View directory record Official record
Conditions
HIV
Interventions
CVCTPLUS
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older · Male only
Enrollment
586 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
4
States / cities
Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Oct 29, 2026, 10:26 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

NCT03914612
View directory record Official record
Conditions
Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Recurrent Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Endometrial Dedifferentiated Carcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Endometrial Mixed Cell Adenocarcinoma, Recurrent Endometrial Serous Adenocarcinoma, Recurrent Endometrial Undifferentiated Carcinoma, Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Interventions
Carboplatin, Computed Tomography, Paclitaxel, Pembrolizumab, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
Drug · Procedure · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
370
States / cities
Birmingham, Alabama • Anchorage, Alaska • Goodyear, Arizona + 272 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 29, 2026, 10:26 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Effect of cTBS on Startle and TMS-evoked BOLD

NCT07415772
View directory record Official record
Conditions
Anxiety
Interventions
Active TMS, Sham TMS
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 50 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 29, 2026, 10:26 AM EDT
Enrolling by invitation Not applicable Interventional

Hippocampal Network Function in Epilepsy

NCT06521437
View directory record Official record
Conditions
Mesial Temporal Lobe Epilepsy
Interventions
TMS targeting the hippocampus indirectly via its network
Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 29, 2026, 10:26 AM EDT
Not listed Not applicable Interventional

Study of Arginine Metabolism and Nitric Oxide Formation in Relation to Glutamine Supply in Severely Burned Patients

NCT00216970
View directory record Official record
Conditions
Burns
Interventions
Alteration in nutritional support
Dietary Supplement
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 13, 2009 · Synced Oct 29, 2026, 10:26 AM EDT
Active, not recruiting Phase 1 Interventional Results available

Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer

NCT04250545
View directory record Official record
Conditions
Leptomeningeal Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Sapanisertib, Telaglenastat Hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
7
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 2 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 29, 2026, 10:26 AM EDT
Active, not recruiting Phase 2 Interventional

Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker

NCT04334941
View directory record Official record
Conditions
Extensive Stage Lung Small Cell Carcinoma
Interventions
Atezolizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Talazoparib
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
561
States / cities
Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 362 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 29, 2026, 10:26 AM EDT
Terminated Phase 2 Interventional Results available

Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

NCT03256045
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Carfilzomib, Chemosensitivity Assay, Dexamethasone, Laboratory Biomarker Analysis, Panobinostat
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Oct 29, 2026, 10:26 AM EDT
Completed Phase 4 Interventional

Hyperpolarized Imaging for New Treatments

NCT04259970
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Initiation of CFTR Modulator
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 18 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
Cincinnati, Ohio • Charlottesville, Virginia • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 29, 2026, 10:26 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)

NCT04439227
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
Adavosertib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 29, 2026, 10:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Test the Outdoor Usage for Sunscreen Products in Female Adults

NCT02779270
View directory record Official record
Conditions
Sunscreening Agents
Interventions
BAY987518, Sunscreen Lotion (U77-030 Control)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Oct 29, 2026, 10:26 AM EDT
Completed Not applicable Interventional Results available

Treatment of Older Veterans With Chronic Posttraumatic Stress Disorder

NCT00539279
View directory record Official record
Conditions
Combat Disorders, Post-traumatic Stress Disorder
Interventions
Prolonged Exposure Therapy (PE), Relaxation Training (RT)
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
60 Years and older · Male only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2015 · Synced Oct 29, 2026, 10:26 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Longitudinal Performance of Epi proColon

NCT03218423
View directory record Official record
Conditions
Colorectal Cancer, Colorectal Neoplasms
Interventions
Epi proColon
Device
Lead sponsor
Epigenomics, Inc
Industry
Eligibility
50 Years to 74 Years
Enrollment
4,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
6
States / cities
San Diego, California • Royal Oak, Michigan • New Brunswick, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 29, 2026, 10:26 AM EDT
Recruiting Phase 1 Interventional

Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes

NCT05687110
View directory record Official record
Conditions
Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Diagnostic Imaging Testing, Novobiocin Sodium
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
22
States / cities
Duarte, California • Irvine, California • La Jolla, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 29, 2026, 10:26 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer

NCT04345913
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Copanlisib Hydrochloride, Eribulin Mesylate, Magnetic Resonance Imaging
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
43
States / cities
Sacramento, California • Derby, Connecticut • Fairfield, Connecticut + 34 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 29, 2026, 10:26 AM EDT